1xlx
From Proteopedia
(Difference between revisions)
(7 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
- | [[Image:1xlx.png|left|200px]] | ||
- | + | ==Catalytic Domain Of Human Phosphodiesterase 4B In Complex With Cilomilast== | |
+ | <StructureSection load='1xlx' size='340' side='right'caption='[[1xlx]], [[Resolution|resolution]] 2.19Å' scene=''> | ||
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[1xlx]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1XLX OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=1XLX FirstGlance]. <br> | ||
+ | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.19Å</td></tr> | ||
+ | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CIO:CILOMILAST'>CIO</scene>, <scene name='pdbligand=CME:S,S-(2-HYDROXYETHYL)THIOCYSTEINE'>CME</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=1xlx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1xlx OCA], [https://pdbe.org/1xlx PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=1xlx RCSB], [https://www.ebi.ac.uk/pdbsum/1xlx PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=1xlx ProSAT]</span></td></tr> | ||
+ | </table> | ||
+ | == Function == | ||
+ | [https://www.uniprot.org/uniprot/PDE4B_HUMAN PDE4B_HUMAN] Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents.<ref>PMID:10846163</ref> <ref>PMID:15003452</ref> | ||
+ | == Evolutionary Conservation == | ||
+ | [[Image:Consurf_key_small.gif|200px|right]] | ||
+ | Check<jmol> | ||
+ | <jmolCheckbox> | ||
+ | <scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/xl/1xlx_consurf.spt"</scriptWhenChecked> | ||
+ | <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview03.spt</scriptWhenUnchecked> | ||
+ | <text>to colour the structure by Evolutionary Conservation</text> | ||
+ | </jmolCheckbox> | ||
+ | </jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=1xlx ConSurf]. | ||
+ | <div style="clear:both"></div> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | Phosphodiesterases (PDEs) comprise a large family of enzymes that catalyze the hydrolysis of cAMP or cGMP and are implicated in various diseases. We describe the high-resolution crystal structures of the catalytic domains of PDE4B, PDE4D, and PDE5A with ten different inhibitors, including the drug candidates cilomilast and roflumilast, for respiratory diseases. These cocrystal structures reveal a common scheme of inhibitor binding to the PDEs: (i) a hydrophobic clamp formed by highly conserved hydrophobic residues that sandwich the inhibitor in the active site; (ii) hydrogen bonding to an invariant glutamine that controls the orientation of inhibitor binding. A scaffold can be readily identified for any given inhibitor based on the formation of these two types of conserved interactions. These structural insights will enable the design of isoform-selective inhibitors with improved binding affinity and should facilitate the discovery of more potent and selective PDE inhibitors for the treatment of a variety of diseases. | ||
- | + | Structural basis for the activity of drugs that inhibit phosphodiesterases.,Card GL, England BP, Suzuki Y, Fong D, Powell B, Lee B, Luu C, Tabrizizad M, Gillette S, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim SH, Schlessinger J, Zhang KY Structure. 2004 Dec;12(12):2233-47. PMID:15576036<ref>PMID:15576036</ref> | |
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | + | </div> | |
- | + | <div class="pdbe-citations 1xlx" style="background-color:#fffaf0;"></div> | |
- | + | ||
==See Also== | ==See Also== | ||
- | *[[Phosphodiesterase|Phosphodiesterase]] | + | *[[Phosphodiesterase 3D structures|Phosphodiesterase 3D structures]] |
- | + | == References == | |
- | == | + | <references/> |
- | < | + | __TOC__ |
- | + | </StructureSection> | |
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
- | [[Category: Artis | + | [[Category: Large Structures]] |
- | [[Category: Bollag | + | [[Category: Artis DR]] |
- | [[Category: Card | + | [[Category: Bollag G]] |
- | [[Category: England | + | [[Category: Card GL]] |
- | [[Category: Fong | + | [[Category: England BP]] |
- | [[Category: Gillette | + | [[Category: Fong D]] |
- | [[Category: Ibrahim | + | [[Category: Gillette S]] |
- | [[Category: Kim | + | [[Category: Ibrahim PN]] |
- | [[Category: Lee | + | [[Category: Kim S-H]] |
- | [[Category: Luu | + | [[Category: Lee B]] |
- | [[Category: Milburn | + | [[Category: Luu C]] |
- | [[Category: Powell | + | [[Category: Milburn MV]] |
- | [[Category: Schlessinger | + | [[Category: Powell B]] |
- | [[Category: Suzuki | + | [[Category: Schlessinger J]] |
- | [[Category: Tabrizizad | + | [[Category: Suzuki Y]] |
- | [[Category: Zhang | + | [[Category: Tabrizizad M]] |
- | + | [[Category: Zhang KYJ]] | |
- | + | ||
- | + |
Current revision
Catalytic Domain Of Human Phosphodiesterase 4B In Complex With Cilomilast
|
Categories: Homo sapiens | Large Structures | Artis DR | Bollag G | Card GL | England BP | Fong D | Gillette S | Ibrahim PN | Kim S-H | Lee B | Luu C | Milburn MV | Powell B | Schlessinger J | Suzuki Y | Tabrizizad M | Zhang KYJ